Drug intelligence / Profile preview

G9-280

Development stage: Unknown
Modality: Peptides
Administration: Subcutaneous

Overview

G9-280 is a synthetic peptide derived from the melanocytic lineage-specific antigen gp100. It is designed to bind to HLA-A2 molecules on antigen-presenting cells, thereby stimulating specific cytotoxic T lymphocytes (CTLs) in HLA-A2+ melanoma patients. This mechanism aims to induce a measurable antitumor immune response against gp100-expressing melanoma cells. A modified version, G9-280-9V, has been developed to enhance its binding affinity to HLA-A2.

Other names: tyrosyl-leucyl-glutamyl-prolyl-glycyl-prolyl-valyl-threonyl-alanine

Targets

HLA-A (HLA class I histocompatibility antigen A alpha chain)

Beyond the preview

Go deeper on G9-280.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G9-280.

Explore the full profile